News

SITC poster presentation

  • 10:47

Society for Immunotherapy of Cancer (SITC) has accepted Immunicum’s poster containing clinical data from INTUVAX – HCC I/II… Read more

RCC I/II improved survival data

  • 10:54

Immunicum presents continued improvement in phase I/II survival data for INTUVAX-treated renal cancer patients Immunicum initiated a phase… Read more

CD70 patent in the US

  • 14:07

Immunicum today announced that the United States Patent and Trademark Office (USPTO) intends to grant a patent relating to… Read more

CD70 patent in China

  • 09:03

Immunicum announces that a patent application in China regarding the Company’s CD70-technology will be granted. Press release 160726… Read more

IND application

  • 15:31

Immunicum today announced that the Company has submitted an Investigational New Drug (IND) application to the Food and Drug… Read more

Chief Medical Officer

  • 12:24

Immunicum announced today that Peter Suenaert, M.D., Ph.D., has accepted the offer to take the role as the Company’s… Read more

Preliminary melanoma plans

  • 09:35

Immunicum announced preliminary plans to conduct two separate studies with INTUVAX for the treatment of advanced melanoma in… Read more

Outcome Rights Issue

  • 10:37

Immunicum’s rights issue of approximately SEK 111 million, which ended on June 14, 2016, was oversubscribed. In view… Read more